Laura S. Danielson
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Paediatric therapeutic development workshop on osteosarcoma.
Journal: British journal of cancer
Published: April 07, 2026
Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.
Journal: British journal of cancer
Published: February 04, 2026
Paediatric therapeutic development workshop on medulloblastoma.
Journal: British journal of cancer
Published: December 13, 2025
Paediatric Therapeutic Development Workshop on rhabdoid tumours.
Journal: British journal of cancer
Published: July 25, 2025
Mind the gap: why we need to consider teenage and young adult cancers across the research pipeline.
Journal: Trends in cancer
Published: May 09, 2024
SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma.
Journal: Endocrine-related cancer
Published: January 10, 2019
Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.
Journal: Brain : a journal of neurology
Published: August 03, 2017
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.
Journal: Brain pathology (Zurich, Switzerland)
Published: February 08, 2017
Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.
Journal: Molecular oncology
Published: December 16, 2016
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Journal: Disease models & mechanisms
Published: December 15, 2015
Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.
Journal: Cancer research
Published: December 27, 2014
Last Updated: 09/26/2026